Imprime PGG + cetuximab + paclitaxel + carboplatin

Imprime PGG + cetuximab + paclitaxel + carboplatin is a multi-agent investigational combination for cancer therapy, primarily studied in advanced solid tumors such as non-small cell lung cancer and breast cancer. **Imprime PGG** is a soluble yeast β-1,3/1,6-glucan biologic that modulates innate immunity by activating the Dectin-1 pathway, priming myeloid cells, dendritic cells, and natural killer cells, and enhancing antigen presentation and cytotoxic T cell responses. **Cetuximab** is a monoclonal antibody targeting the Epidermal Growth Factor Receptor, blocking ligand binding and signaling. **Paclitaxel** is a cytotoxic small molecule that stabilizes microtubules and inhibits cell division. **Carboplatin** is a cytotoxic platinum compound that forms DNA crosslinks leading to apoptosis. The combination leverages immune modulation (Imprime PGG), targeted therapy (cetuximab), and cytotoxic chemotherapy (paclitaxel and carboplatin) for synergistic anti-tumor effects, demonstrated by enhanced innate and adaptive immune responses and increased tumor cell killing in preclinical and clinical settings[1][2][6].

Other names

cetuximabpaclitaxelcarboplatinImprime PGG + cetuximab + paclitaxel + carboplatin